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Abstract
Background: More than seventeen million Americans are afflicted with diabetes and these people
have four times the rate of coronary heart disease (CHD) as non-diabetics. Furthermore, diabetic
women have a 3.8 fold greater risk for CHD compared to diabetic men. Little is known why
diabetic women are at an increased risk for CHD. It is possible that diabetic women with
cardiovascular disease (CVD) have a greater inflammatory response resulting in an increased
platelet neutrophil conjugate formation than diabetic men with CVD or non-diabetic women with
CVD. This study tested the hypothesis that platelet-neutrophil conjugates, which are associated
with several cardiovascular diseases, are increased in diabetic women with CVD compared to
diabetic men with CVD and non-diabetic women with CVD.
Methods: Platelet-neutrophil conjugates were quantified by flow cytometry. The primary method
is through direct binding of the neutrophil PSGL-1 receptor with P-selectin expressed on the
platelet.
Results: In this study, we found when the blood was stimulated with PAF (platelet activating
factor), diabetic women without CVD demonstrated an increase in platelet-neutrophil conjugates
compared to diabetic women with CVD and non-diabetic women with CVD (% conjugates: 63.3 ±
5.2 vs 46.8 ± 4.3 vs 48.6 ± 3.4, p < 0.05). The stimulation ratio was significantly increased in diabetic
and non-diabetic women with CVD in comparison to diabetic men with CVD (ratio: 3.3 ± 0.4 vs
3.3 ± 0.3 vs 2.1 ± 0.3, p < 0.05).
Conclusion: These results suggest that platelets and neutrophils in diabetic women have a greater
potential for activation compared to diabetic men and may contribute to thrombosis/inflammation
and the greater severity of coronary heart disease observed in diabetic women as compared to
diabetic men.
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Background
Diabetes poses a significant risk factor for cardiovascular
disease in both men and women, but the incidence of type
2 diabetes is markedly greater in women [1]. It is known
that diabetic women have a significantly greater risk and
severity of cardiovascular disease than diabetic men. Dia-
betic women have an elevated base line risk, and have
more cardiovascular risk factors than men [2]. From the
Framingham Heart Study, diabetic women have an age-
adjusted risk ratio of 3.8 for coronary heart disease (CHD)
compared to diabetic men. Despite the importance of
complicating factors in the severity of heart disease in dia-
betes, little is known about the interrelationships of risk
factors and cardiovascular disorders, particularly in dia-
betic women. Of particular interest is the inflammatory
response and its effect on cardiovascular disease. The
inflammatory response complicates cardiovascular dis-
ease in several ways [3]. It was observed that diabetic men
with cardiovascular disease exhibit chronic inflammation
[4]. Since inflammation amplifies atherosclerosis and
ischemia-reperfusion injury, it is important to investigate
if this complication is exacerbated in diabetic women.
An enhanced inflammatory response may contribute to
the greater rate, recurrence and severity of myocardial inf-
arction and ischemic heart failure in diabetes. From recent
laboratory ischemia-reperfusion studies, it appears that
reperfusion injury following ischemia is exacerbated in
type 1 diabetes [5]. Neutrophils accumulate in the coro-
nary microcirculation following ischemia, amplifying
reperfusion injury in diabetic hearts [6,7]. Platelets are
known to mediate the activation of leukocytes. Our labo-
ratory demonstrated that when the platelet and neu-
trophil interaction is inhibited, ROS production is
decreased. These experiments were performed in men, but
very little is known about the cell-mediated inflammatory
response in diabetic women, or how it compares to the
inflammatory response of men.
The aim of this study was to investigate the severity of
platelet-neutrophil conjugates in diabetic men and dia-
betic women with ischemic heart disease. We evaluated
the formation of platelet and neutrophil conjugates in
non-diabetic women without cardiovascular disease, non-
diabetic women with cardiovascular disease, diabetic
women without cardiovascular disease, diabetic women
with cardiovascular disease, non-diabetic men with cardi-
ovascular disease, and diabetic men with cardiovascular
disease. We found the stimulation ratio was significantly
greater in diabetic and non-diabetic women with CVD in
comparison to diabetic men with CVD, suggesting dia-
betic women's blood is hyper-reactive to stimulation com-
pared to diabetic men's blood. These results indicate that
platelets and neutrophils in diabetic women have a
greater potential for activation compared to diabetic men.
Platelet-neutrophil conjugates may contribute to throm-
bosis/inflammation and the greater severity of coronary
heart disease observed in diabetic women as compared to
diabetic men.
Table 1: Demographics of the women and men.
Patient Characteristics NDW-CVD 
(n = 23)
NDW+CVD 
(n = 25)
DW-CVD 
(n = 20)
DW+CVD 
(n = 24)
NDM+CVD 
(n = 8)
DM+CVD 
(n = 18)
Age (years) 58.5 ± 1.7 66.0 ± 2.5*** 55.7 ± 2.6 65.4 ± 2.2*** 63.8 ± 3.4 64.9 ± 2.5
Body Mass Index (kg/m2) 26.8 ± 1.0 28.8 ± 1.4** 36.9 ± 1.8* 29.9 ± 1.5 28.2 ± 1.3 29.2 ± 1.0
Duration of Diabetes (years) N/A N/A 9.2 ± 1.5 14.3 ± 3.2 N/A 14.5 ± 3.4
HbA1c (%) 5.4 ± 0.1 5.2 ± 0.2** 8.2 ± 0.4* 6.9 ± 0.3* *** 5.9 ± 0.4 7.4 ± 0.4
Hypertension (%)ψ 8% 76% 55% 67% 50% 83%
Hypercholesteremia (%)ψ 25% 64% 53% 71% 100% 56%
Current Smoker (%) 0% 20% 10% 8% 38% 22%
Prior Cardiovascular Events (%)
Myocardial Infarction ψ 0% 52% 0% 63% 63% 73%
Strokeψ 0% 12% 0% 17% 38% 17%
PTCAψ 0% 20% 0% 33% 25% 75%
CABGψ 0% 20% 0% 25% 75% 33%
*P < 0.05 compared to NDW-CVD group **P < 0.05 compared to DW-CVD group ***P < 0.05 compared to NDW+CVD group ψ The 
proportions are significantly related (P < 0.05) Non-diabetic women without cardiovascular disease (NDW-CVD), Non-diabetic women with 
cardiovascular disease (NDW+CVD), Diabetic women without cardiovascular disease (DW-CVD), and diabetic women with cardiovascular disease 
(DW+CVD), Non-diabetic men with cardiovascular disease (NDM+CVD), and Diabetic men with cardiovascular disease (DM+CVD).Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/12
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Methods
Subjects
Four groups of women were studied; non-diabetic women
without cardiovascular disease (NDW-CVD) (n = 23),
non-diabetic women with cardiovascular disease
(NDW+CVD) (n = 25), diabetic women without cardio-
vascular disease (DW-CVD) (n = 20), and diabetic women
with cardiovascular disease (DW+CVD) (n = 24). Two
groups of men were studied; non-diabetic men with cardi-
ovascular disease (NDM+CVD) (n = 8) and diabetic men
with cardiovascular disease (DM+CVD) (n = 18). These
patients were enrolled from the patients attending the
Cardiology Clinic at the Veterans Administration Hospital
(Tucson, AZ) and the Diabetes Clinic at the University of
Arizona Medical Center (Tucson, AZ). The protocol was
approved by the University of Arizona Institutional
Review Board. Patient's characteristics are summarized in
Table 1 and their medications are summarized in Table 2.
Fifteen milliliters of blood were drawn in a citrate tube
from all the patients. The severity of diabetes was deter-
mined by the patient's hemoglobin A1C. A subject was
considered to have cardiovascular disease if they had a
previous cardiovascular event (myocardial infarction, cor-
onary artery bypass graft (CABG), stroke, percutaneous
coronary intervention (PCI), or some combination).
Platelet-Neutrophil Conjugates
The platelet-neutrophil conjugates were determined by
measuring fluorescent markers specific to platelets and
leukocytes. The leukocytes were labeled by mixing whole
blood with an equal volume of solution containing LDS-
751 (Molecular Probes). Platelets were measured as the
fluorescence of a PE-conjugated antibody (Pharmingen)
against CD42b (GPIb). Through the use of these two dif-
ferent colored probes, it was possible to gate the events
using the flow cytometer. These events were then desig-
nated the platelet-neutrophil conjugates.
Since P-selectin is the main receptor by which platelets
and neutrophils form conjugates, we used an antibody
against P-selectin to block the formation of the conjugates
in order to confirm that we were actually observing plate-
let-neutrophil conjugates. Platelet-neutrophil conjugates
were blocked with a purified P-selectin (CD62) antibody
(Pharmingen). In this experiment the WB/LDS, GPIb anti-
body, and anti-P-selection were combined in respective
tubes, covered and incubated at room temperature for 15
minutes. To determine the effects of acute stimulation on
platelet-neutrophil conjugate formation, PAF was added
to respective tubes and incubated for another 10 minutes.
After 25 minutes, ice-cold PBS was added and the samples
were put on ice until analyzed on the flow cytometer (Bec-
ton Dickinson FACScan Clinical Flow Cytometer). Side
scatter and Forward scatter were used to back-gate and
identify the neutrophil population in the whole blood
sample. The neutrophil population was then analyzed for
the co-expression of the PE-GPIb probe to obtain a popu-
lation of platelet and neutrophil conjugates (see figure 1).
The neutrophils were then analyzed to determine the
response to P-selectin blockade and PAF stimulation.
Data was acquired and stored in list-mode for analysis of
percent positive events and mean channel of fluorescence
[4]
Estradiol Measurement
We examined the estrogen levels in the women to deter-
mine if there was a difference among the groups, possibly
influencing the platelet-neutrophil conjugate formation.
Table 2: Distribution of medications in women and men.
Medication (%) NDW-CVD 
(n = 23)
NDW+CVD 
(n = 25)
DW-CVD 
(n = 20)
DW+CVD 
(n = 24)
NDM+CVD 
(n = 8)
DM+CVD 
(n = 18)
Beta Blockersψ 0% 48% 10% 46% 50% 53%
Diureticsψ 4% 20% 10% 63% 50% 71%
Nitratesψ 4% 16% 0% 21% 0% 53%
ACE Inhibitorsψ 4% 20% 65% 38% 63% 41%
Positive Intropes 0% 8% 5% 21% 0% 12%
Ca2+ Channel Blockersψ 0% 16% 10% 29% 38% 29%
Aspirinψ 2 1 %5 6 %2 5 %7 9 %6 3 %5 9 %
Anti-coagulants 0% 12% 10% 4% 25% 0%
Antioxidantsψ 50% 28% 10% 13% 0% 0%
Hypoglycemic Agentsψ 0% 0% 65% 21% 0% 29%
Statins 12% 29% 25% 34% 75% 38%
HRT 50% 64% 55% 42% N/A N/A
ψ The proportions are significantly related (P < 0.05) Non-diabetic women without cardiovascular disease (NDW-CVD), Non-diabetic women with 
cardiovascular disease (NDW+CVD), Diabetic women without cardiovascular disease (DW-CVD), and diabetic women with cardiovascular disease 
(DW+CVD), Non-diabetic men with cardiovascular disease (NDM+CVD), and Diabetic men with cardiovascular disease (DM+CVD).Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/12
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Representative FACS plots to assess platelet-neutrophil conjugates in a diabetic woman with cardiovascular disease Figure 1
Representative FACS plots to assess platelet-neutrophil conjugates in a diabetic woman with cardiovascular disease. (A) 
Unstimulated blood (22.4% of platelet-neutrophil conjugates). (B) Stimulated blood (75.9% of platelet-neutrophil conjugates). 
(C) Inhibited blood (3.5% of platelet-neutrophil conjugates).
A
B
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The blood samples were centrifuged (Megafuge 1.0 R, Bax-
ter Scientific Products) at 2,500 RPM for thirty minutes at
4°C. The plasma was pipetted from each sample and then
immediately stored at -70°C. Once a sufficient number of
samples were collected, they were removed from the
freezer and thawed to room temperature. The estradiol
was measured using a double antibody 125I radioimmu-
noassay from DPC. All samples were run in duplicate. The
samples were prepared according to the directions pro-
vided by the company. Standard tubes were made and
100  µL of Estradiol Antiserum was added to all tubes
except the nonspecific binding and the total count tubes.
The samples were incubated for 2 hours at room temper-
ature and then 100 µL of 125I Estradiol was added to all
tubes. The samples were then incubated for one hour at
room temperature. Cold precipitating solution was added
to all tubes and the samples were incubated for 10 min-
utes at room temperature. Finally, the samples were cen-
trifuged for 15 minutes at 3000 × g and the supernatant
was decanted. The precipitate was retained for counting.
Each tube was counted for one minute. The values of
estradiol were obtained in pg/mL from a logit-log repre-
sentation of the calibration curve.
Data Analysis
Data were collected in notebooks and transferred to a
Computer Spreadsheet Format (Excel for Windows). The
summary results are represented as mean ± standard error
of the mean (SEM). Comparisons among the four groups
were made with an ANOVA (Sigma-Stat 3.0). A Dunn's
and Holm-Sidak Post hoc test was performed (Sigma-Stat
3.0). A Chi squared test was performed to determine if the
percentages in table 1 and 2 were significantly related. P <
0.05 was considered as statistically significant.
Results
Patient Characteristic
Table 1 summarizes the characteristics of the six groups
studied. There was a significant difference of age in the
NDW+CVD and DW+CVD groups compared to the
NDW-CVD and DW-CVD groups (p < 0.05). There was
also a significant difference in body mass index (BMI) of
the NDW+CVD group compared to DW-CVD group (p <
0.05) and DW-CVD group compared to NDW-CVD group
(p < 0.05). There was no significant difference in the dura-
tion of diabetes among the three diabetic groups. The gly-
cated hemoglobin (HbA1C) was significantly greater in
DW-CVD and DW+CVD compared to NDW-CVD (p <
0.05). The glycated hemoglobin (HbA1C) was also signifi-
cantly greater in DW-CVD compared to NDW+CVD and
DW+CVD compared to NDW+CVD (p < 0.05). There was
a significant difference in hypertension and hypercholes-
teremia among the groups. There were no significant dif-
ferences in smoking among any of the groups. The various
drug therapies that the patients were receiving are summa-
rized in Table 2. There was no significant difference in the
percentages of women taking HRT or statins among any of
the groups. There was a significant difference in the per-
centages of women taking beta blockers, diuretics,
nitrates, ACE inhibitors, antioxidants, aspirin, and
hypoglycemic agents.
Platelet-Neutrophil Conjugates
Figure 2 exhibits three pictures demonstrating platelet-
neutrophil interaction in unstimulated blood from a non-
diabetic woman without cardiovascular disease, stimu-
lated blood (with PAF) from a diabetic man with cardio-
vascular disease, and stimulated blood (with PAF) from a
diabetic woman with cardiovascular disease. Figure 3A
reports the percentage of platelet-neutrophil conjugates
measured in diabetic and non-diabetic women with and
without cardiovascular disease. There is a trend toward
increased platelet-neutrophil conjugates in diabetic
women with cardiovascular disease in comparison to the
other groups of women, but no statistical significance. Fig-
ure 3B reports the percentage of platelet-neutrophil conju-
gates measured in diabetic and non-diabetic men and
women with cardiovascular disease. There was no signifi-
cance among the groups of women and men.
Platelet-Neutrophil Conjugates after Stimulation with PAF
The percentage of platelet-neutrophil conjugates was
increased in all groups after stimulation with PAF. Figure
4A reports the percentage of platelet-neutrophil conju-
gates after stimulation measured in diabetic and non-dia-
betic women with and without cardiovascular disease.
The greatest response to PAF stimulation was observed in
the diabetic women without CVD. NDW+CVD and
DW+CVD had significantly less platelet-neutrophil conju-
gates after stimulation in comparison to DW-CVD (p <
0.05). Figure 4B reports the percentage of platelet-neu-
trophil conjugates after stimulation measured in diabetic
and non-diabetic men and women with cardiovascular
disease.
Platelet-Neutrophil Conjugates reactivity to PAF
As an indicator of the reactivity to acute stimulation, we
calculated the ratio of PAF stimulated to unstimulated
conjugates. Figure 5A reports the platelet-neutrophil con-
jugate reactivity to PAF measured in diabetic and non-dia-
betic women with and without cardiovascular disease.
NDW+CVD and DW+CVD had significantly less platelet-
neutrophil conjugate reactivity to PAF in comparison to
DW-CVD (P < 0.05). Figure 5B reports the platelet-neu-
trophil conjugate reactivity to PAF measured in diabetic
and non-diabetic men and women with cardiovascular
disease. NDW+CVD and DW+CVD had significantly
greater platelet-neutrophil conjugate reactivity to PAF in
comparison to DM+CVD (P < 0.05).Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/12
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Pictures demonstrating platelet-neutrophil interaction Figure 2
Pictures demonstrating platelet-neutrophil interaction. (A) Unstimulated blood from a non-diabetic woman without cardiovas-
cular disease. (B) Stimulated blood (with PAF) from a diabetic man with cardiovascular disease. (C) Stimulated blood (with 
PAF) from a diabetic woman with cardiovascular disease.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/12
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(A) Summary of percent of platelet-neutrophil conjugates for women in the study Figure 3
(A) Summary of percent of platelet-neutrophil conjugates for women in the study. Comparison of non-diabetic women without 
cardiovascular disease (NDW-CVD) versus non-diabetic women with cardiovascular disease (NDW+CVD) versus diabetic 
women without cardiovascular disease (DW-CVD) versus diabetic women with cardiovascular disease (DW+CVD). There is 
no significant difference among any of these groups. (B) Summary of percent of platelet-neutrophil conjugates for women and 
men in the study. Comparison of non-diabetic men with cardiovascular disease (NDM+CVD) versus non-diabetic women with 
cardiovascular disease (NDW+CVD) versus diabetic men with cardiovascular disease (DM+CVD) versus diabetic women with 
cardiovascular disease (DW+CVD). There is no significant difference among any of the groups.
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(A) Summary of percent of platelet-neutrophil conjugates after stimulation with PAF for women in the study Figure 4
(A) Summary of percent of platelet-neutrophil conjugates after stimulation with PAF for women in the study. Comparison of 
non-diabetic women without cardiovascular disease (NDW-CVD) versus non-diabetic women with cardiovascular disease 
(NDW+CVD) versus diabetic women without cardiovascular disease (DW-CVD) versus diabetic women with cardiovascular 
disease (DW+CVD). NDW+CVD and DW+CVD had significantly less platelet-neutrophil conjugates after stimulation in com-
parison to DW-CVD (P < 0.05). (B) Summary of percent of platelet-neutrophil conjugates after stimulation with PAF for 
women and men in the study. Comparison of non-diabetic men with cardiovascular disease (NDM+CVD) versus non-diabetic 
women with cardiovascular disease (NDW+CVD) versus diabetic men with cardiovascular disease (DM+CVD) versus diabetic 
women with cardiovascular disease (DW+CVD). There is no significant difference among any of the groups.
*P<0.05 compared to DW-CVD group
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(A) Summary of platelet-neutrophil conjugate reactivity to PAF for women in the study Figure 5
(A) Summary of platelet-neutrophil conjugate reactivity to PAF for women in the study. Comparison of non-diabetic women 
without cardiovascular disease (NDW-CVD) versus non-diabetic women with cardiovascular disease (NDW+CVD) versus 
diabetic women without cardiovascular disease (DW-CVD) versus diabetic women with cardiovascular disease (DW+CVD). 
NDW+CVD and DW+CVD had significantly less stimulation ratio of platelet-neutrophil conjugates in comparison to DW-
CVD (P < 0.05). (B) Summary of platelet-neutrophil conjugate reactivity to PAF for women and men in the study. Comparison 
of non-diabetic men with cardiovascular disease (NDM+CVD) versus non-diabetic women with cardiovascular disease 
(NDW+CVD) versus diabetic men with cardiovascular disease (DM+CVD) versus diabetic women with cardiovascular disease 
(DW+CVD). NDW+CVD and DW+CVD had significantly greater stimulation ratio of platelet-neutrophil conjugates in com-
parison to DM+CVD (P < 0.05).
*P<0.05 compared to DW-CVD group
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Platelet-Neutrophil Conjugates after Inhibition with anti-
P-selectin
The percentage of platelet-neutrophil conjugates after P-
selectin blockade was measured. We performed this exper-
iment to confirm that we were examining platelet-neu-
trophil conjugates via the p-selectin receptor. P-selectin
blockade markedly reduced the conjugate formation. Fig-
ure 6A reports the platelet-neutrophil conjugates after P-
selectin blockade measured in diabetic and non-diabetic
women with and without cardiovascular disease. The
blockade caused an overall 76% decrease in the conjugate.
Figure 6B reports the platelet-neutrophil conjugates after
P-selectin blockade measured in diabetic and non-dia-
betic men and women with cardiovascular disease. The
blockade caused an overall 75% decrease in the conjugate.
Estradiol Levels
The estradiol levels were measured in diabetic and non-
diabetic women with and without cardiovascular disease.
There was no significant difference among any of the
groups (Figure 7). Estradiol in non-diabetic women
without cardiovascular disease was 22.1 ± 7.3. Estradiol in
non-diabetic women with cardiovascular disease was 30.6
± 8.0. Estradiol in diabetic women without cardiovascular
disease was 30.2 ± 9.3. Estradiol in diabetic women with
cardiovascular disease was 37.0 ± 14.0.
Discussion
Gender differences in the pathology of cardiovascular dis-
ease have not been studied extensively. There was a reduc-
tion in the overall death rate due to cardiovascular disease
(CVD) in the United States during the last several decades,
but the CVD reduction was less for women than men.
Coronary heart disease (CHD) and stroke are the leading
killers of women in the United States. Fifty percent of
women will eventually die of heart disease or stroke. Sev-
eral reports document that a women with CHD has a
worse prognosis than men with CHD. This might indicate
an increased severity of illness at presentation [8,9]. Dia-
betes mellitus is an even stronger risk factor for CHD in
women than in men. Diabetes is associated with three to
sevenfold elevation in CHD risk among women com-
pared with a two to threefold elevation among men [8].
Another report indicated that the prevalence rate ratio for
CHD in individuals with type 2 diabetes was 4.6 in
women compared to 1.8 in men [1]. Despite the marked
difference, little is known about the pathogenesis of cardi-
ovascular disease in diabetes to explain the discrepancy in
diabetic men and diabetic women.
One possible explanation is that the inflammatory
response is more marked in women. Inflammation is now
considered a primary cardiovascular risk factor and a
recent study of predictors of cardiovascular risk ranks
markers of inflammation, such as C-reactive protein, as
comparable to markers of cholesterol [3,10]. It is known
that inflammation mediates the formation of atheroscle-
rotic plaque, the major cause of cardiovascular dysfunc-
tion. We hypothesized that one possible element of the
pathogenesis of cardiovascular disease in diabetes, plate-
let-neutrophil conjugates, a result of inflammation, is dif-
ferent in diabetic women and diabetic men. Rinder et al.
reports 15% + 1.5% of platelet-neutrophil conjugates in
patients prior to cardiopulmonary bypass [11] and we
found 15% + 1.5% of platelet-neutrophil conjugates in
healthy age matched controls. We did not find the chronic
baseline concentrations of platelet-neutrophil conjugates
to be significantly different among any of the groups stud-
ied. We did however observe that after stimulation with
PAF (platelet activating factor), a signaling molecule
released with ischemia and reperfusion [12], the percent-
age of platelet-neutrophil conjugates was significantly less
in non-diabetic women with cardiovascular disease and
diabetic women with cardiovascular disease compared to
diabetic women without cardiovascular disease. These
results indicate that there might be some blunting effect
after stimulation in women with cardiovascular disease
regardless of their diabetic status.
When comparing men to women there were no chronic
differences observed. The most intriguing results were
found when comparing the response to acute stimulation
of platelet-neutrophil conjugates. It was observed that
non-diabetic women with cardiovascular disease and
diabetic women with cardiovascular disease had a signifi-
cantly increased reactivity to PAF in comparison to dia-
betic men with cardiovascular disease. These results
suggest that women's blood may be more reactive to acute
stimulus that occurs under ischemic conditions than dia-
betic men's blood. Platelet-neutrophil conjugates may
contribute to thrombosis/inflammation and the greater
severity of coronary heart disease observed in diabetic
women as compared to diabetic men [13].
Platelet-Neutrophil Conjugate Formation
The primary interaction between platelets and leukocytes
is via the P-selectin receptor (CD62) on the platelets and
the P-selectin glycoprotein ligand-1 (PSGL-1) on leuko-
cytes [14–22]. P-selectin, which is stored in α-granules of
platelets and in Weibel-Palade bodies of endothelial cells,
is translocated to the cellular surface within 5 to 15 min-
utes after stimulation with histamine, thrombin, or oxy-
gen radicals [23–27]. The binding of platelets to
leukocytes was demonstrated in vitro to cause the expres-
sion of pro-inflammatory cytokines, an oxidative burst,
increased expression of cell adhesion molecules like Mac-
1, induce neutrophil activation, and generate signals that
promote integrin activation [28–33]. Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/12
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(A) Summary of inhibition of platelet-neutrophil conjugates with anti-P-selectin for women in the study Figure 6
(A) Summary of inhibition of platelet-neutrophil conjugates with anti-P-selectin for women in the study. Comparison of non-
diabetic women without cardiovascular disease (NDW-CVD) versus non-diabetic women with cardiovascular disease 
(NDW+CVD) versus diabetic women without cardiovascular disease (DW-CVD) versus diabetic women with cardiovascular 
disease (DW+CVD). NDW-CVD and DW-CVD had significantly less platelet-neutrophil conjugates in comparison to 
NDW+CVD (P < 0.05). DW+CVD had significantly greater platelet-neutrophil conjugates in comparison to DW-CVD (P < 
0.05). (B) Summary of inhibition of platelet-neutrophil conjugates with anti-P-selectin for women and men in the study. Com-
parison of non-diabetic men with cardiovascular disease (NDM+CVD) versus non-diabetic women with cardiovascular disease 
(NDW+CVD) versus diabetic men with cardiovascular disease (DM+CVD) versus diabetic women with cardiovascular disease 
(DW+CVD). There is no significant difference among any of the groups.
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Platelet-Neutrophil Conjugates in Cardiovascular Disease
Platelet-neutrophil conjugates were observed in various
cardiovascular disease states [34]. Neumann et al. deter-
mined that after an acute myocardial infarction (AMI) leu-
kocyte-platelet adhesion was increased and remained
elevated for at least five days after PTCA. It was concluded
that the platelet-leukocyte conjugates might contribute to
inflammatory responses in acute coronary syndromes
[29]. A study by Morse et al. reported that during cardiop-
ulmonary bypass (CPB) patients have significantly acti-
vated platelets (increase of P-selectin) and neutrophils
(increase of CD11b) [35]. A study by Gawaz et al. reported
platelet-leukocyte adhesion was increased in patients with
symptomatic coronary heart disease compared to normal
controls. It was also determined that when stimulated,
patients with symptomatic coronary heart disease had a
hyper-reactive response, which could indicate an
increased risk of acute thrombotic event [36].
The role of platelet-neutrophil conjugates in ischemia-
reperfusion injury was investigated. A study by Lefer et al.
examined the effects of neutrophils and platelets
separately and together, but not platelet-neutrophil con-
jugates, in causing cardiac dysfunction in perfused rat
hearts after ischemia and reperfusion (I/R). It was demon-
strated that I/R hearts perfused with neutrophils or plate-
lets alone exhibited a decreased of 10% to 12% of heart
functions and when neutrophils and platelets were per-
fused together, the various heart functions decreased by
50% to 60%. This study also demonstrated that blocking
of P-selectin decreased the synergism between the plate-
lets and neutrophils. The possible mechanism of the
decrease in cardiac function in this experiment includes
neutrophil and platelet aggregates obstructing the flow of
the coronary microvessels. Platelets and neutrophils can
also release many toxic components, which could then
decrease the coronary flow and the cardiac contractility
[37]. Another study by Kogaki et al. found that the pres-
ence of activated platelets increased neutrophil adhesion
and migration after hypoxia-reoxygenation and this was
inhibited with an anti-P-selectin antibody. They hypothe-
sized that the increased neutrophil adhesion and migra-
Summary of estradiol for all women in the study Figure 7
Summary of estradiol for all women in the study. Comparison of non-diabetic women without cardiovascular disease (NDW-
CVD) versus non-diabetic women with cardiovascular disease (NDW+CVD) versus diabetic women without cardiovascular 
disease (DW-CVD) versus diabetic women with cardiovascular disease (DW+CVD). There is no significant difference among 
any of the groups.
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tion via P-selectin and subsequent neutrophil activation
[27].
Interaction between Platelets and Neutrophils
There is a complex interaction that occurs platelets and
neutrophils. Activated platelets act as stimuli for neu-
trophils, but platelets may also inhibit neutrophil activa-
tion. Conversely, neutrophils affect platelets. Platelet and
neutrophil cross talk may affect the development of
thrombotic and inflammatory diseases [38]. Platelets not
only play a role in hemostasis but also play a role in
inflammation via releasing substances with physiologic
potential and by interacting with leukocytes and vascular
endothelial cells involved in modulation of the inflam-
matory reaction [39]. There are several components
released by stimulated platelets induce neutrophil activa-
tion and chemotaxis [40–43].
Activated neutrophils produce free radicals, which in turn
are potent activators of platelets [44–47]. This evidence of
platelet stimulation of neutrophils and neutrophil stimu-
lation of platelets suggests a positive feedback loop lead-
ing to further stimulation and amplification of tissue
injury [38]. A study by Aziz et al. demonstrated that short-
term incubations of neutrophils with stimulated platelets
causes an increase of oxidative bursts from the neutrophil
[48].
Platelet-Neutrophil Conjugates in Diabetes
There are few reports of platelet-neutrophil conjugates in
diabetic patients [49,50], but there is evidence that diabe-
tes is associated with chronic inflammation. A study by
Vozarova et al. reported that a high white blood cell
(WBC) count predicts the development of type 2 diabetes
and a decrease of insulin action in Pima Indians. The WBC
count was positively correlated with measures of adiposity
and fasting plasma insulin concentration. The authors
hypothesize that a chronic activation of the immune sys-
tem may play a role in the pathogenesis of type 2 diabetes
[51]. Studies by Thorand et al. and Barzilay et al. also
found that low-grade inflammation (in particular
increased C-reactive protein) was predictive of an
increased risk of type 2 diabetes mellitus in middle-aged
and elderly men [52,53].
Implications of Platelet-Neutrophil Conjugates
Platelet aggregation in atherosclerotic coronary arteries
contributes to acute myocardial ischemia. After coronary
artery occlusion and reperfusion, leukocytes become acti-
vated, sequester in the microcirculation and release oxy-
gen free radicals and proteolytic enzymes. The radicals
and enzymes may be responsible for progression of vascu-
lar and cardiomyocyte injury [54]. Superoxide radical-
mediated endothelial injury causes smooth muscle con-
traction and decreased endothelium contraction [55]. The
vascular injury from the oxygen free radicals may then
cause a decrease of coronary blood flow reserve and coro-
nary reactivity after reperfusion [56,57]. The physical
obstruction of the microvascular bed by activated leuko-
cytes and decreased neutrophil deformability are possible
factors by which leukocytes contribute to vascular injury
seen in ischemic coronary artery disease [5,6,54,58,59].
Platelet-neutrophil interaction localizes both cells but
also creates an optimal environment for the exchange of
mediators and metabolites [14]. Binding of platelets to
leukocytes modulates a variety of leukocyte function
including cytokine synthesis [60–62] , surface expression
of adhesion receptors, like CD11/CD18 [28,63], and oxi-
dative burst [54].
Conclusion
Diabetic patients have an increased risk of cardiovascular
disease; which is much more severe in diabetic women.
One of the links between diabetes and cardiovascular dis-
ease is inflammation. Hayden et al. hypothesized that
type 2 diabetes mellitus is a vascular disease (atheroscle-
rosis) and that NOS, NO, and redox stress, components of
inflammation, play a causative role in type 2 diabetes, in
turn causing atherosclerosis [64]. An increase in WBC,
pro-inflammatory cytokines, and C-reactive protein are all
linked to the development of diabetes. Inflammation con-
tributes to the development of atherosclerosis, creating a
more severe lesion. Inflammation is now considered a pri-
mary risk factor for cardiovascular disease [3,10]. In this
study we decided to examine one component of inflam-
mation, platelet-neutrophil conjugates, in six groups of
diabetic and non-diabetic patients with and without car-
diovascular disease. We found an increased propensity for
female blood to form conjugates in response to acute
stimulation. An increase in platelet-neutrophil conjugates
in diabetic patients could potentially be one of the factors
causing more severe cardiovascular disease in diabetic
patients, particularly women. We also examined the dif-
ferences of estradiol levels in the women to determine if
estrogen levels were a possible explanation for the differ-
ences in inflammation, but there was no significant
difference in estradiol levels between any of the groups.
This implies that estrogen is not playing a role in the dif-
ferences of platelet-neutrophil conjugates that we found.
In conclusion, the findings of this study indicate that: 1.)
the baseline concentrations of platelet-neutrophil conju-
gates were not significantly different among any of the
groups studied, 2.) after stimulation with PAF, the per-
centage of platelet-neutrophil conjugates were signifi-
cantly decreased in non-diabetic women with
cardiovascular disease and diabetic women with cardio-
vascular disease compared to diabetic women without
cardiovascular disease, and 3.) non-diabetic women withCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/12
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cardiovascular disease and diabetic women with cardio-
vascular disease had significantly increased conjugate
reactivity compared to diabetic men with cardiovascular
disease. There was a significant increase in the age of the
women with cardiovascular disease in comparison to
women without cardiovascular and this could possibly
effect the results. Another influence on the results could
be the different drug therapies that the patients are on. In
particular, statins are known to reduce inflammation via
decreasing concentrations of C-reactive protein and
upregulating endothelial nitric oxide synthase [65,66].
We found that the proportions of patient on statins are
not significantly different among groups, making statins
less likely to influence the results. Another observation
that was made was the decreased amount of diabetic
women without cardiovascular disease that were on aspi-
rin therapy. This group demonstrated an increase in plate-
let-neutrophil conjugates after stimulation with PAF. This
could be a result of the lack of aspirin therapy in this
group. One of the limitations of this study is that diabetic
patients without cardiovascular disease could include
patients with silent coronary disease. Another limitation
is that a multivariant analysis was not performed.
These results suggest that one of the potential causes of the
difference of severity of cardiovascular disease between
diabetic men and diabetic women is the diabetic women's
propensity to hyper-react to an acute ischemic stimulus
and activate platelet-neutrophil conjugates more than
that of diabetic men. The increased number of neutrophil-
neutrophil conjugates may localize both cell types in the
microcirculation causing obstruction and ROS release. In
addition, the complex activation of each of the cells by the
other could occur creating a positive feed back loop of
increased inflammatory activation. This increase in
inflammation may then possibly increase the severity of
thrombosis and cardiovascular disease.
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